EECA CAB position statements on Janssen, Gilead and Pharmasyntez
The position statements focus on the drugs for treating HIV (Janssen, Gilead, Pharmasyntez), HCV (Janssen, Gilead) and TB (Janssen, Pharmasyntez).
The EECA CAB recently met with Gilead, Janssen and Pharmasyntez.
See below the links to EECA CAB position statements on each company and their policies.
http://eeca-cab.org/en/2010/05/06/gilead/#eeca_cab_position
http://eeca-cab.org/en/2010/05/06/janssen-johnsonjohnson/#eeca_cab_position
http://eeca-cab.org/en/2013/06/01/Pharmasyntez/#eeca_cab_position
The Eastern European and Central Asian Community Advisory Board (EECA CAB) is established in 2009 to improve access to treatment for HIV, hepatitis C and TB using the joint forces of the patient communities in these two regions. The EECA CAB is made up of treatment access advocates from Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Ukraine, Uzbekistan and Estonia.
